Holen Sie sich die Stockscreener-App
55.23
4.61%
-2.67
Handel nachbörslich:
55.64
0.41
+0.74%
Xenon Pharmaceuticals Inc Aktie (XENE) Neueste Nachrichten
Xenon Pharmaceuticals (XENE) sets June 2, 2026 annual shareholder meeting and April 7 record date - Stock Titan
Xenon Pharmaceuticals closes $747.5M public offering - Investing.com South Africa
Xenon Pharmaceuticals closes US $747.5M public offering - Private Capital Journal
Xenon Pharmaceuticals Closes $747.5 Million Public Offering - marketscreener.com
BofA raises Xenon Pharmaceuticals price target on trial success - Investing.com
Xenon Pharmaceuticals Nets $707.7 Million in $57 Share Offering With Pre-Funded Warrants - TradingView
Xenon Pharmaceuticals closes $747.5M public offering By Investing.com - Investing.com UK
Xenon Pharmaceuticals Announces Closing of $747.5 Million - GlobeNewswire
Xenon Pharmaceuticals launches $500 million stock offering By Investing.com - Investing.com Nigeria
The Azetukalner Breakthrough: A Deep Dive into Xenon Pharmaceuticals (XENE) - The Chronicle-Journal
Is Xenon Pharmaceuticals (XENE) Pricing Look Compelling After Recent 37% Weekly Share Surge? - simplywall.st
What is HC Wainwright's Estimate for XENE FY2027 Earnings? - MarketBeat
Xenon Pharmaceuticals shares jump 40% after strong Phase 3 seizure trial results - MSN
Ian Mortimer Sells 11,269 Shares of Xenon Pharmaceuticals (NASDAQ:XENE) Stock - MarketBeat
Xenon Pharmaceuticals (NASDAQ:XENE) CEO Ian Mortimer Sells 270,000 Shares - MarketBeat
Insider Selling: Xenon Pharmaceuticals (NASDAQ:XENE) Insider Sells 2,771 Shares of Stock - MarketBeat
Xenon Pharmaceuticals (NASDAQ:XENE) Insider Sells $156,706.77 in Stock - MarketBeat
XENE Expands Stock Offering to $650 Million - GuruFocus
Xenon Pharmaceuticals prices $650M public offering at $57/share - Investing.com Australia
Xenon Pharmaceuticals prices $650M public offering at $57/share By Investing.com - Investing.com Nigeria
Xenon Pharmaceuticals (NASDAQ:XENE) Sees Large Volume Increase on Analyst Upgrade - MarketBeat
Xenon Pharmaceuticals Prices Upsized $650 Million Public Offering of Shares - marketscreener.com
Liquidity Mapping Around (XENE) Price Events - Stock Traders Daily
Xenon Pharmaceuticals (XENE) Upsizes Public Offering to $650 Mil - GuruFocus
Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering - GlobeNewswire
Xenon Raises $650 Million in Upsized U.S. Equity Offering - TipRanks
Xenon Pharmaceuticals announces pricing of upsized $650.0 million public offering - marketscreener.com
Xenon Pharmaceuticals Inc. Prices Upsized Public Offering, Anticipated Gross Proceeds of Approximately $650 Million - Quiver Quantitative
Biotech Xenon raises $650M in stock sale at $57 a share - Stock Titan
Xenon Pharmaceuticals Announces Pricing Of Upsized $650.0 Million Public Offering - TradingView
Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering - GlobeNewswire Inc.
[144] Xenon Pharmaceuticals Inc. SEC Filing - Stock Titan
XENE Stock Up as Azetukalner Meets Goal in Focal Onset Seizures Study - Bitget
Why Xenon Pharmaceuticals (XENE) Is Up 38.4% After Strong Phase 3 Azetukalner Seizure Data And FDA Plans - simplywall.st
Xenon Pharmaceuticals announces proposed $500M public share offering - MSN
Xenon Pharmaceuticals: Buy Rating Backed by Superior X-TOLE2 Phase 3 Results and Commercial Upside for Azetukalner in Focal Epilepsy - TipRanks
XENE: Wells Fargo Raises Price Target by 38.78% on Overweight Ra - GuruFocus
The Potassium Channel Breakthrough: A Deep-Dive on Xenon Pharmaceuticals (XENE) - FinancialContent
Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says - MarketBeat
XENE: Wedbush Raises Price Target for Xenon Pharmaceuticals | XE - GuruFocus
Xenon Pharmaceuticals (NASDAQ:XENE) Price Target Raised to $64.00 at Wedbush - MarketBeat
Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Deutsche Bank Aktiengesellschaft Issues Positive Forecast for Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price - MarketBeat
XENE: HC Wainwright Raises Price Target for Xenon Pharmaceuticals | XENE Stock News - GuruFocus
Xenon Pharmaceuticals stock reaches all-time high at 60.5 USD By Investing.com - Investing.com Canada
XENE Announces Positive Phase 3 Results for Epilepsy Treatment - GuruFocus
50% and 61% Gains in a Single Day: Why XENE and RLMD Soared Today - AOL.com
XENE Stock Rallies 50% On Epilepsy Trial Data, But One Analyst Thinks Rival Biohaven Still Has ‘Room To Differentiate’ - Stocktwits
Xenon’s Seizure Drug Data Make A Strong Case For Clinical Use - Citeline News & Insights
Xenon Pharmaceuticals’ Strategic Moves Signal New Opportunities in Epilepsy Screening - timothysykes.com
Xenon Pharmaceuticals Announces Proposed Public Offering - TradingView
Xenon Pharmaceuticals (XENE) Launches $500M Public Offering - GuruFocus
Why This Biotech, Up 47%, Could Spark The Next Buyout Frenzy - Investor's Business Daily
Xenon Pharmaceuticals launches $500 million stock offering - Investing.com India
Guggenheim Maintains Buy on Xenon Pharmaceuticals Inc. (XENE) March 2026 - Meyka
Xenon Pharmaceuticals Launches $500 Million Public Share Offering - TipRanks
Jefferies raises Xenon Pharmaceuticals stock price target on epilepsy drug potential - Investing.com
Crude oil rises around 4%; Xenon Pharmaceuticals shares surge - MSN
Guggenheim raises Xenon Pharmaceuticals stock price target on trial data - Investing.com UK
Guggenheim raises Xenon Pharmaceuticals stock price target on trial data By Investing.com - Investing.com Nigeria
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):